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ABSTRACT
Objective: To describe and evaluate the use of
cognitive-based behaviour change techniques as
interventions to improve medication adherence.
Design: Systematic review and meta-analysis of
interventions to improve medication adherence.
Data sources: Search of the MEDLINE, EMBASE,
PsycINFO, CINAHL and The Cochrane Library
databases from the earliest year to April 2013 without
language restriction. References of included studies
were also screened to identify further relevant articles.
Review methods: We used predefined criteria to
select randomised controlled trials describing a
medication adherence intervention that used
Motivational Interviewing (MI) or other cognitive-based
techniques. Data were extracted and risk of bias was
assessed by two independent reviewers. We conducted
the meta-analysis using a random effects model and
Hedges’ g as the measure of effect size.
Results: We included 26 studies (5216 participants)
in the meta-analysis. Interventions most commonly
used MI, but many used techniques such as aiming to
increase the patient’s confidence and sense of self-
efficacy, encouraging support-seeking behaviours and
challenging negative thoughts, which were not
specifically categorised. Interventions were most
commonly delivered from community-based settings
by routine healthcare providers such as general
practitioners and nurses. An effect size (95% CI) of
0.34 (0.23 to 0.46) was calculated and was statistically
significant (p < 0.001). Heterogeneity was high with an
I2 value of 68%. Adjustment for publication bias
generated a more conservative estimate of summary
effect size of 0.21 (0.08 to 0.33). The majority of
subgroup analyses produced statistically non-
significant results.
Conclusions: Cognitive-based behaviour change
techniques are effective interventions eliciting
improvements in medication adherence that are likely
to be greater than the behavioural and educational
interventions largely used in current practice. Subgroup
analyses suggest that these interventions are amenable
to use across different populations and in differing
manners without loss of efficacy. These factors may
facilitate incorporation of these techniques into routine
care.
INTRODUCTION
Estimates suggest that 30–50% of patients
prescribed medications for chronic illnesses
do not adhere to their prescribed medication
regimen.1 This non-adherence has been
ARTICLE SUMMARY
Article focus
▪ Medication non-adherence is widespread and
represents a notable barrier in achieving optimal
effects from therapeutic intervention.
▪ Despite the magnitude and consequences of
non-adherence, a gold standard intervention to
improve it remains elusive.
▪ Cognitive-based behaviour change techniques
(CBCTs) may represent a useful tool in improv-
ing medication adherence, but their use in this
domain has not been established using
meta-analytic techniques.
Key messages
▪ CBCTs are effective interventions for improving
medication adherence and capable of eliciting
improvements in adherence beyond those
achieved with educational and behavioural inter-
ventions which form the mainstay of current
practice.
▪ According to the results of subgroup analyses,
CBCTs can be effectively delivered by routine
healthcare providers, and the effectiveness of
interventions is not associated with intervention
exposure.
▪ Healthcare providers may wish to consider
incorporation of these techniques into their
medication adherence consultations.
Strengths and limitations of this study
▪ The studies pooled in this meta-analysis are
restricted to randomised controlled trials, which
strengthens their robustness.
▪ Techniques to account for publication bias have
been utilised to provide a conservative effect size
estimate offering robustness to our estimate.
▪ Notable heterogeneity was reported when studies
were combined, which may be a limitation.
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demonstrated to diminish treatment effect which can
result in prolonged illness, additional investigations and
prescriptions that may otherwise have been unneces-
sary.2 A link between poor adherence and an increased
risk of mortality is also well established.3 Consequently,
the WHO has described non-adherence as ‘a worldwide
problem of striking magnitude’ and a priority for health-
care researchers and policymakers.1
Despite the magnitude and potential gravity of sub-
optimal medication adherence, a gold standard inter-
vention remains elusive; a recent Cochrane review
highlighted the paucity of effective interventions in
current practice.4 Evidence suggests that complex, multi-
faceted interventions tailored to meet individual needs
are most likely to be efﬁcacious,4 5 which is intuitive
given the complex, multistage process that is taking
medication.
Non-adherent behaviour is traditionally categorised into
unintentional and intentional. Unintentional non-
adherence includes behaviours arising from forgetfulness,
misunderstanding and confusion. Intentional non-
adherence describes patient choice that deviates from the
prescribed medication regimen. Unintentional and inten-
tional non-adherence are not mutually exclusive; thus, an
amalgam of these behaviours often exists in any one
patient. An understanding of patient behaviour and its
underpinning psychology plus the wealth of factors, both
internal and external that may inﬂuence medication
taking, is crucial to understand how to change patient
behaviour and thus improve medication adherence.6
Historically, adherence interventions have encom-
passed behaviour change techniques such as simplifying
dosage regimens and providing adherence aids or edu-
cation to address the practical issues of adherence in
terms of knowing how and being able to take the medi-
cation as prescribed. Pooled data for such studies have
demonstrated marginal effects,4 yet such interventions
continue to form the cornerstone of routine healthcare
provision.2 These interventions may have particularly
poor efﬁcacy in cases of intentional non-adherence as
the provision of persuasive advice may evoke further
resistance to change.7 8 Through an understanding of
the challenges faced in changing behaviours and the
motivation necessary to achieve change, novel, cognitive-
based behaviour change techniques (CBCTs) have
emerged. These interventions aim to change a patient’s
behaviour by altering their thoughts, feelings, conﬁ-
dence or motivation to adhere. CBCT interventions can
vary widely in content such as incorporating techniques
to enhance patient sense of self-efﬁcacy, problem solve
and increase motivation to adhere.
Motivational Interviewing (MI) is one of the most
widely recognised CBCTs and is designed to facilitate
behaviour change by resolving patient ambivalence
about change.9 It therefore primarily targets intentional
non-adherence but also enables patients to reﬂect on
any unintentional barriers to adherence and seek out
solutions. Systematic reviews and meta-analyses have
reported MI efﬁcacy in facilitating health-related behav-
iour change such as smoking cessation and alcohol with-
drawal10–16 but have not explored its effects on
medication adherence. Adaptations of MI such as
Behaviour Change Counselling17 additionally allow the
facilitator to educate and advise, and thus application to
both intentional and unintentional non-adherence may
be effective.
Best practice guidelines state that evidence of interven-
tion efﬁcacy should ideally be pooled from the literature
in a systematic review or meta-analysis wherever possible
to offer a robust and cohesive evidence base.18 This
study provides a systematic review and meta-analysis of
MI and other cognitive-based techniques as interven-
tions to improve medication adherence.
METHODS
We used standard systematic review methods18 19 and
registered the study protocol (PROSPERO register refer-
ence CRD42011001721). Randomised controlled trials
(RCTs) reporting an adherence intervention using MI
and/or other cognitive-based techniques with medica-
tion adherence as an outcome measure were eligible for
inclusion. All deﬁnitions of adherence, such as the per-
centage of doses taken over a given time period and per-
centage of patients achieving a speciﬁed adherence
level, were considered. All adherence measures were
also considered, including self-report and electronic
monitoring. Where multiple measures were reported,
the percentage of patients achieving a speciﬁed adher-
ence level was selected as this was common to more
studies.
Any intervention using some form of psychological
technique to change a patient’s adherence behaviour, as
well as their thoughts, feelings, conﬁdence or motivation
towards adherence, was deﬁned as a cognitive-based
technique. Studies examining adherence to medications
for the treatment of addiction and/or mental health
conditions were excluded as these interventions tend to
be speciﬁc to these domains.
Search strategies
We developed a search strategy to avoid restriction to
predetermined terms such as ‘motivational interviewing’
as many of the techniques of interest are not classiﬁed
using speciﬁc or consistent terms. MeSH terms were also
used to enhance retrieval of relevant studies.
Truncations (*), wild cards ($), hyphens and other rele-
vant Boolean operators were used where permitted.
Scoping searches were conducted prior to ﬁnalising the
search strategy to ensure suitability of terms in generat-
ing a good coverage of relevant material.
We applied the search strategy (as shown in online
supplementary appendix 1) to the MEDLINE, EMBASE,
PsychINFO, CINAHL and Cochrane databases in April
2013 without date or language restrictions. The
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reference lists of all screened full-text articles were also
used to identify further relevant articles.
Study selection and data extraction
Two researchers (CE and EP) independently screened
titles and abstracts against the inclusion and exclusion
criteria using a piloted abstract screening tool.
Inter-reviewer agreement using Cohen’s κ was assessed
for the abstract and full-text screening stages. The level
of agreement was characterised using a qualitative
scale.20 Discrepancies were resolved by discussion
between the two reviewers and, if necessary, referral to a
third independent reviewer (DB) until consensus was
reached.
Data extraction was also undertaken by CE and EP,
independently using piloted forms. Data extracted
included study details (such as year and journal of publi-
cation, country and study design); study characteristics
(including setting, population, delivery methods and
personnel); intervention details (including intervention
type, duration and principal components) and outcome
details (including adherence assessment measure, data
and deﬁnition). A list of intervention components was
independently extracted from the articles verbatim by
two reviewers. Grouping of similar components was
undertaken by one reviewer and veriﬁed by a second
reviewer.
Accuracy of data collected was veriﬁed by comparison
of the forms completed by the two independent
reviewers. In cases of discrepancy, consensus was agreed
through discussion and, where necessary, referral to a
third independent reviewer (DB). For studies with
missing data or ambiguities, the corresponding author
was contacted for clariﬁcation.
Quality assessment
A quality assessment of all included studies was made
using the Cochrane risk of bias tool.18 The risk of bias
was assessed in ﬁve domains deemed relevant to the
included studies: random sequence generation, alloca-
tion concealment, blinding of outcome assessment,
incomplete outcome data and selective reporting.
Performance bias (blinding of participants and person-
nel) was not included as the nature of the interventions
meant that blinding of participants and personnel was
impossible in almost all studies. None of the included
studies were found to contain additional sources of
potential bias not represented by the ﬁve included
domains. The risk of bias for each study, in each of the
ﬁve domains, was classiﬁed as low, uncertain or high, as
recommended in the guidelines.18 The quality assess-
ment process was undertaken independently by two
reviewers, with consensus on the ﬁnal risk classiﬁcations
reached through discussion.
Data analysis
The meta-analysis was conducted using STATA (V.12.1).
Given the broad inclusion criteria, we anticipated
including studies from different populations with different
diseases and which used different CBCTs. We therefore
explored heterogeneity via calculation of the I2 statistic,
which describes the percentage of total variation across
studies that is due to heterogeneity rather than
chance.21 22 A random effects model (DerSimonian-Laird
method) was employed to calculate a pooled effect size
(Hedges’ g) and 95% CI for the included studies.23
Calculation of the effect size as Hedges’ g (standardised
difference in means) enabled adherence outcome mea-
sures of differing deﬁnition and measure to be combined,
transforming this data into a common metric. When SD
was missing, we estimated SE of mean difference based on
reported p values, means and the number of patients. ORs
were converted to standardised mean differences by using
the formula SMD=lnOR×√3/π.23
Funnel plots were produced where appropriate to
explore potential publication biases. STATA (V.12.1) was
used to conduct Egger’s test24 to test funnel plot asym-
metry. We used the trim-and-ﬁll method25 26 to estimate
a summary effect size after adjusting for asymmetric
funnel plots.
Variables of interest in inﬂuencing the effect size and
informing intervention design were determined a priori
and the following subgroup analyses undertaken using a
random effects meta-regression: intervention components,
setting, delivery personnel, delivery method and interven-
tion exposure, disease area and risk of bias. The type of
outcome measure used to assess adherence (objective
compared with subjective) was added as a post hoc sub-
group analysis to further explore heterogeneity. Objective
outcome measures included electronic monitoring and
pill counts, while subjective measures included all forms of
self-report. Differences between subgroups were tested
using the STATA ‘metareg’ command for random-effects
univariate meta-regression analysis.
RESULTS
Study selection, characteristics and quality
Figure 1 shows the number of papers excluded at each
stage of the review. Of the 442 abstracts screened, 84
studies passed the abstract screening stage with moder-
ate agreement between the two reviewers (κ=0·57).
Conﬂict in classifying an intervention as a CBCT
accounted for 31% of discrepancies and was heavily
inﬂuenced by a paucity of information in the abstracts.
At the full-text screening stage, agreement between the
two independent reviewers was much higher, with a κ
value of 0.91, indicating almost perfect agreement. After
examining 84 full-text articles, we included 26 (31%) in
the meta-analysis.
The main characteristics of the 26 included studies
are summarised in table 1. The studies provided a total
sample size of 5216 participants and were primarily
undertaken in the USA, followed by the UK,27–29
Australia30 31 and the Netherlands.32 33 Dates of publica-
tion ranged from 1990 to 2012 with only two studies
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(7.7%) predating 2000.28 34 Ten (38.5%) were published
within the last 5 years (2008–2013). The most common
condition for which medications were prescribed was
HIV, accounting for 14 (53.8%) studies. Other studies
concerned treatments for a range of conditions includ-
ing asthma,32 34 35 diabetes27 31 and hypertension.30 36
Just over half of the included studies (53.8%)
described an intervention with a clearly deﬁned CBCT;
MI was most commonly used and this was the case for
11 (42.3%) studies.30 31 36–44 A further three (11.5%)
studies used Implementation Intention Interventions
(III, also known as if-then planning) as a clearly deﬁned
CBCT. For 12 (46.2%) studies, a clearly deﬁned CBCT,
such as MI, could not be identiﬁed;32–35 45–52 these
studies are identiﬁed in table 1 as ‘multiple components;
non-speciﬁc techniques’. Instead, this group comprised
multiple components such as ‘providing education’ or
‘increasing patient knowledge’, which was reported in
nine (75%) studies in this group. Other components
included ‘increasing self-efﬁcacy’ and ‘developing or
improving problem solving skills’, each reported in six
(50) studies and ‘identifying and resolving adherence
barriers’ and ‘increasing social support’, each of which
was also reported in six studies (50%). All studies within
this group included one or more components that
aimed to alter the patient’s thoughts, feelings, motiv-
ation or conﬁdence towards adherence and that could
therefore be classiﬁed as a CBCT. Detailed information
regarding the identiﬁed intervention components
extracted from each study are provided as an online
supplementary table. The majority of interventions had
multiple components. Many studies combined CBCT
with more traditionally used educational (eg, increasing
patient knowledge) and behavioural (eg, regimen sim-
pliﬁcation and provision of dosing aids) components.
Interventions were most commonly delivered in
person, from community-based settings and by routine
healthcare providers such as nurses, pharmacists and
general medical practitioners. ‘Non-routine’ healthcare
providers were considered to be those such as psycholo-
gists or psychotherapists, who would not ordinarily be
involved in the patient’s care.
The intervention period ranged from four (15·4%)
studies reporting singular sessions, to six (23·1%)
studies reporting multiple sessions over 12 months. The
median (IQ) number of sessions over which interven-
tions were delivered was 5 (3–7.3). The majority of inter-
ventions were delivered over a period of 6 months or
Figure 1 Flow diagram for selection of studies.
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Table 1 Characteristics of included studies in meta-analysis
Study Study setting
Disease
area Intervention description*
Identified
intervention
components
Components
received by
control group
Sample
size
Intervention
delivery style
(and
personnel)
Intervention
length
(average)
Bailey et al34 Hospital clinic,
USA
Asthma Comprehensive programme
integrating a skill-orientated
self-help workbook with one-to-one
counselling and
adherence-enhancing strategies
Multiple components;
non-specific
techniques
Standard care;
education via a
standardised
set of
pamphlets and
routine
physician
encouragement
225 Telephone
calls and in
person
(specialist)
240 min
(4×60 min
sessions) over
unknown
period
Berger et al40 Telephone calls to
patients at home,
USA
Multiple
sclerosis
Software-supported intervention
based on transtheoretical model of
change and MI
Motivational
Interviewing (MI)
Standard care
plus could
telephone help
line
367 Telephone
calls
(researcher)
9 sessions of
unknown
duration
delivered over
3 months
Brown et al29 Hospital clinic, UK Epilepsy Formation of III via completion of a
self-administered questionnaire
Implementation
Intention
Interventions (III)
Standard care
plus self-report
questionnaires
69 Questionnaire
completion
(not in person)
One-off
intervention of
unknown
duration
DiIorio et al41 Community clinic,
USA
HIV One-to-one counselling sessions
based on MI
MI Standard care;
usual
adherence
education
provided in the
clinic
17 In person
(routine HCP)
5×35 min
sessions
delivered over
12 months
DiIorio et al42 Hospital clinic,
USA
HIV MI as individual counselling
sessions
MI Standard care;
usual
(extensive)
education
provided at the
clinic
213 Mostly in
person with
some
telephone
calls (routine
HCP)
5 sessions of
35 min over
12 months
Farmer et al27 Community-based
clinic, UK
Type 2
diabetes
Brief intervention to elicit beliefs,
resolve barriers and form ‘if-then’
plans
If-then planning (III) Standard care
plus additional
clinic visits for
blood tests
211 In person
(clinic nurse)
One-off
session
lasting 30 min.
George et al30 Community
pharmacies,
Australia and
Tasmania
Hypertension Community pharmacy intervention
of one-to-one sessions, monitoring
and medication review
MI Standard care 343 In person
(routine HCP)
3 sessions of
unknown
duration over
6 months
Continued
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Table 1 Continued
Study Study setting
Disease
area Intervention description*
Identified
intervention
components
Components
received by
control group
Sample
size
Intervention
delivery style
(and
personnel)
Intervention
length
(average)
Golin et al39 Community clinic,
USA
HIV Multicomponent MI-based
intervention
MI General HIV
information
provided via
audio tape, two
one-to-one
sessions and
two mail shots
117 In person
(specialist)
2 sessions of
unknown
duration over
2 months
Hovell et al51 Hospital clinic,
USA
Tuberculosis Adherence coaching involving
interviewing, contingency
contracting and shaping
procedures
Multiple components;
non-specific
techniques
Standard care;
routine advice
at appointments
188 Telephone
calls and in
person
(researcher)
12 sessions of
15–30 min
over 6 months
Konkle-Parker
et al38
Community-based
clinics and
patients’ own
homes, USA
HIV Adherence intervention guided by
the
Information-Motivation-Behavioural
Skills (IMB) model
MI Standard care;
usual clinic
appointments
36 Telephone
calls and in
person (nurse
practitioner)
8 sessions
over
24 weeks.
Average
overall
duration 1 h
30 min
Maneesriwongul
et al37
Hospital
outpatients clinic
and telephone
calls to patients at
home, Thailand
HIV MI with counselling MI Standard care;
education and
provision of
leaflets at point
of prescribing
60 Telephone
calls and in
person
(researcher)
3 sessions
approximately
30 min over a
4 week period
Murphy et al52 Community-based
clinic, USA
HIV Multicomponent and
multidisciplinary intervention
including behavioural strategies
and cognitive behavioural therapy
Multiple components;
non-specific
techniques
Standard care;
regular
appointments
with enquiries
about
adherence and
an additional
30 min
appointment for
those with
problems where
medication
schedule is
written down for
them
33 In person
(specialist)
5 sessions of
unknown
duration over
7 weeks
Continued
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Table 1 Continued
Study Study setting
Disease
area Intervention description*
Identified
intervention
components
Components
received by
control group
Sample
size
Intervention
delivery style
(and
personnel)
Intervention
length
(average)
Ogedegbe
et al36
Community clinic,
USA
Hypertension Practice-based MI counseling MI Standard care;
usual
appointments
plus additional
visits for MEMS
downloads
160 In person
(researcher)
4 sessions
lasting 30–
40 min
delivered over
12 months
Pradier et al50 Hospital clinic,
France
HIV Educational and counselling
intervention founded in the
principles of motivational
psychology and client-centred
therapy
Multiple components;
non-specific
techniques
Standard care;
routine
follow-up
appointments
202 In person
(routine HCP)
3 sessions of
45–60 min
over 3 months
Put et al35 Hospital clinic,
Belgium
Asthma Behavioural change intervention
involving psycho-education with
behavioural and cognitive
techniques
Multiple components;
non-specific
techniques
Standard (no
details
provided)
23 In person
(researcher)
360 min
(6×60 min
sessions) over
3 months
Remien et al49 Community-based
clinic, USA
HIV Couples-based intervention
grounded in social action theory
Multiple components;
non-specific
techniques
Standard care;
education at
point of
prescribing and
follow-up to
check
adherence and
investigate/
address
underlying
causes of any
non-adherence
196 In person
(routine HCP)
4 sessions of
45–60 min
over 5 weeks
Safren et al44 Community clinic,
USA
HIV Single session minimal treatment
intervention using cognitive
behavioural, MI and problem
solving techniques
MI Minimal contact
intervention;
daily diary used
to record no. of
pills prescribed
and taken each
day
53 In person
(routine HCP)
One-off
intervention of
unknown
duration
Continued
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Table 1 Continued
Study Study setting
Disease
area Intervention description*
Identified
intervention
components
Components
received by
control group
Sample
size
Intervention
delivery style
(and
personnel)
Intervention
length
(average)
Sheeran and
Orbell28
Visits to patient’s
own home, UK
Vitamin
Supplements
Formation of III via completion of a
self-administered questionnaire
Implementation
Intention Intervention
(III)
Completion of
same
questionnaire
but without
formation of
implementation
intention
78 Questionnaire
completion
(not in person)
One-off
intervention of
unknown
duration
Simoni et al48 Community-based
clinic and
telephone calls to
patients at home,
USA
HIV Peer-led medication-related social
support intervention
Multiple-components;
non-specific
techniques
Standard care;
education
programme and
social and
health referrals
as necessary
114 Group
sessions and
individual
telephone
calls (peers)
18 sessions of
unknown
duration over
3 months
Smith et al47 Community-based
research office,
USA
HIV Self-management intervention
based on feedback of adherence
performance and principles of
social cognitive theory
Multiple components;
non-specific
techniques
Standard care;
usual
medication
counselling,
educational
leaflets,
scheduling
support
reminder lists
and discussion
of adherence
strategies
17 In person
(routine HCP)
Four sessions
of unknown
duration over
12 weeks
Solomon et al43 Telephone calls to
patient’s own
home, USA
Osteoporosis Telephone-based counselling
programme rooted in MI
MI Standard care
plus seven
information
mailings on
osteoarthritis
care
2087 Telephone
calls (health
educator)
8 sessions of
14 min over
12 months
Tuldrà et al46 Hospital clinic,
Spain
HIV Psycheducative intervention based
on Self-efficacy theory
Multiple components;
non-specific
techniques
Standard care;
normal clinical
follow-up
77 Unknown
(routine HCP)
7 sessions of
unknown
duration
van Es et al32 Hospital clinic,
Netherlands
Asthma Intervention programme to
stimulate a positive attitude,
increase social support and
enhance self-efficacy
Multiple components;
non-specific
techniques
Standard care;
routine
check-ups
67 In person
(routine HCP)
7 sessions of
30–90 min
over
12 months
Continued
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Table 1 Continued
Study Study setting
Disease
area Intervention description*
Identified
intervention
components
Components
received by
control group
Sample
size
Intervention
delivery style
(and
personnel)
Intervention
length
(average)
Wagner et al45 Community clinic,
USA
HIV Cognitive behavioural intervention
with motivational components,
based on the
information-motivation-behavioural
skills (IMB) model
Multiple components;
non-specific
techniques
Standard care
practices for
improving
adherence;
education,
tailoring
regimen,
offering a
pillbox,
adherence
checks and
enquiries about
side effects
135 In person
(routine HCP)
5 sessions of
30–45 min
over 48 weeks
Weber et al33 Community,
psychotherapy
clinic, Netherlands
HIV Cognitive behavioural intervention
delivered by a psychotherapist
Multiple components;
non-specific
techniques
Standard care
(no details
provided)
53 In person
(specialist)
11 sessions of
45 min over
12 months
Williams et al31 Telephone calls
and visits to
patient’s own
home, Australia
Diabetes Multifactorial intervention consisting
of self-monitoring of blood
pressure, medicine review,
educational DVDs and MI to
support blood pressure control and
optimal medication adherence
MI Standard care
(no details
provided)
75 In person and
phone calls
(specialist)
5 sessions,
one of 89 min
and 4 of an
average of
11.75 min,
over 3 months
*See online supplementary table A for a detailed breakdown of intervention components.
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less, which was the case for 17 studies (65.4%).
Intervention exposure as the total number of minutes
spent delivering the intervention could be estimated for
16 studies. In the remaining 10 studies, these data were
not available. Intervention exposure ranged from 30 min
to 8 h and 15 min. The median (IQR) intervention
exposure was 175 (118–263) min.
The comparison group was ‘standard care’ for all
studies; for 13 studies (50%), standard care involved
some form of technique to improve adherence such as
education, encouragement or provision of adherence
aids and in these studies, recipients of the intervention
received further techniques such as MI.
Supplementary ﬁgures S1 and S2 show the results of
the risk of bias assessment. Only ﬁve (19.2%)
studies27 36 41 48 49 scored ‘low risk’ in all ﬁve bias cat-
egories. Nineteen (73.1%) studies were scored as moder-
ate overall risk, because 2–4 of the categories were
classed as ‘low risk’. Two (7.7%)40 44 studies were classed
as ‘high overall risk’, because only one risk category was
scored as low. The most common source of bias was a
lack of blinding of the outcome assessment; this is
because the measure of adherence was frequently self-
report. Self-report measures of adherence are commonly
used but subject to patient bias. In the majority of cases,
the patients were not blind to their treatment group
allocation, and thus use of self-report measures leaves
scope for bias.
Meta-analysis
Twenty-six RCTs were pooled to assess the effects of
CBCTs on medication adherence. Three studies showed
non-signiﬁcant negative effects on medication adher-
ence, but the remaining 23 studies all showed improve-
ments in medication adherence with receipt of
intervention. The effect size calculated for each study is
summarised in table 2.
Random effects meta-analysis showed evidence that
CBCTs are associated with improved medication adher-
ence. Figure 2 shows the forest plot for the 26 studies
and exempliﬁes the tendency towards positive adher-
ence effects with intervention. A pooled estimate of
effect size (95% CI; reported as Hedges’ g) of 0.34 (0.23
to 0.46) was calculated when all studies were combined,
although heterogeneity was high (I2=68%, 95% CI 52%
to 79%).
The funnel plot produced was indicative of publica-
tion bias (as shown in ﬁgure 3) and thus further
explored using Egger’s test, which conﬁrmed statistically
signiﬁcant funnel plot asymmetry (p=0.005). The
trim-and-ﬁll technique was used to recompute an effect
size which accounted for this asymmetry, yielding a more
conservative effect size estimate of 0.21 (0.08 to 0.33; as
shown in online supplementary ﬁgure S3). This effect
size suggests that CBCTs elicit small but statistically sig-
niﬁcant improvements in medication adherence
(p=0.001) relative to standard care. According to data
from six studies that used the percentage of prescribed
dose taken, the pooled SD of this outcome was 30.7%.
Then a standardised mean difference of 0.205 (0.084 to
0.326) will correspond to a difference of 6.3% (2.6% to
10%) between the intervention and the control groups
in the percentage of dose taken.
Subgroup analyses via meta-regression
Table 3 summarises the results of the subgroup analyses
to explore variations in effect sizes for the predeter-
mined variables. The regression coefﬁcient is the differ-
ence in pooled Hedges’ g between the two subgroups
compared. A coefﬁcient >0 indicates that studies in
subgroup-A reported greater treatment effects than
those in subgroup-B.
The classiﬁcation of studies into subgroups was largely
intuitive. However, as a continuous rather than a categor-
ical variable, ‘total intervention exposure’ was less amen-
able to intuitive dichotomisation. In such instances, it is
standard practice to create two subgroups by distributing
a roughly equal number of studies to each group. An
arbitrary cut-off point of 3 h was therefore used to split
the data into two subgroups.
Interventions delivered from hospital settings were
associated with greater treatment effects compared with
interventions in community or other settings (difference
0.27, 95% CI 0.01 to 0.54, p=0.043). Differences in effect
sizes between subgroups were statistically non-signiﬁcant
in all other cases. However, the subgroup analyses may
have failed to detect important differences between sub-
groups because of the small number of studies included.
As the variable ‘intervention exposure’ was a continu-
ous variable, an additional post hoc analysis was under-
taken. This allowed the variable to be analysed in its
‘natural’ continuous state rather than in two subgroups.
This exploratory analysis was undertaken to ensure that
the arbitrary cut-off point of 3 h had not adversely inﬂu-
enced the data. A coefﬁcient value (95% CI) of 0.001
(−0.001 to 0.002) suggested that there was no associ-
ation between intervention exposure and effect size. A
non-signiﬁcant p value of 0.540 conﬁrmed this and
demonstrates results comparable to the subgroup ana-
lysis for this variable.
DISCUSSION
Principal findings
Receipt of a cognitive-based behavioural adherence
intervention was associated with small but statistically sig-
niﬁcant improvements in medication adherence.
Heterogeneity was high and notable publication bias was
identiﬁed. However, techniques have been used to
account for this bias, resulting in a more conservative
summary effect size of 0.21 (95% CI 0.08 to 0.33;
p=0.001).
In half of the included studies, the standard care
received by the control group explicitly involved some
form of ‘adherence enhancing strategy’ such as provi-
sion of education, monitoring or review. Such strategies
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Table 2 Study outcomes for studies included in meta-analysis
Extracted data
Study
Sample size
(intervention, control) Adherence definition (assessment measure)
Intervention
group Control group p Value
Effect size
(Hedges’ g)
(95% CI)
Bailey et al34 225 (124, 101) Percentage of patients scored as adherent on all
6 items of a self-report scale (based on Morisky’s
self-reported scale)
Mean=91.9 Mean=61.7 0.001 0.44 (0.18 to 0.71)
Berger et al40 367 (172, 195) Percentage of patients discontinuing treatment by
study endpoint (patient interview)
Mean=98.8 Mean=91.3 0.001 0.35 (0.14 to 0.55)
Brown et al29 69 (36, 33) Percentage of prescribed doses taken over a
month (electronic monitoring)
Mean (SD)=93.4
(12.3)
Mean (SD)
=79.1 (28.1)
0.66 (0.18 to 1.14)
DiIorio et al41 17 (8, 9) Mean number of missed medicines in the last
30 days (self-report questionnaire)
Mean (SD)=0.13
(0.35)
Mean (SD)
=0.98 (1.48)
0.73 (−0.21 to 1.67)
DiIorio et al42 213 (107, 106) Percentage of doses taken during the
intervention period (electronic monitoring)
Mean=64 Mean=55 0.09 0.23 (−0.04 to 0.50)
Farmer et al27 211 (126, 85) Percentage of days during a 12-week period in
which medication was taken correctly (electronic
monitoring)
Mean (SD)=77.4
(26.3)
Mean (SD)
=64.0 (30.8)
0.04 0.47 (0.20 to 0.75)
George et al30 343 (170, 173) Percentage of participants classed as adherent
(Morisky self-report scale)
Mean=72.2 Mean=63.8 0.09 0.18 (−0.03 to 0.39)
Golin et al39 117 (59, 58) Percentage of prescribed doses taken in the
month prior to the study endpoint (CAS)
Mean (SD)=76
(27)
Mean (SD)=71
(27)
0.18 (−0.18 to 0.54)
Hovell et al51 188 (92, 96) Cumulative number of doses taken over
9 months (patient interview)
Mean (SD)
=179.93 (57.01)
Mean (SD)
=150.98 (73.75)
0.44 (0.15 to 0.72)
Konkle-Parker et al
38
36 (21,15) Percentage of patients taking >90% of their
medications in the last 3–4 weeks (prescription
refill data)
Mean (SD)=0.93
(0.23)
Mean (SD)
=0.92 (0.27)
0.04 (−0.61 to 0.69)
Maneesriwongul
et al37
60 (30, 30) Mean percentage of doses taken over the last
4 weeks (self-report using a visual analogue
scale)
Mean (SD)=97.1
(3.3)
Mean (SD)
=89.8 (5.6)
1.55 (0.98 to 2.12)
Murphy et al52 33 (17, 16) Percentage of doses taken during the
intervention period (self-report questionnaire)
Mean (SD)=0.86
(0.33)
Mean (SD)
=0.83 (0.36)
0.09 (−0.58 to 0.75)
Ogedegbe et al36 160 (79, 81) Percentage of days during a 2-month period in
which medication was taken correctly (electronic
monitoring)
Mean=56.9 Mean=42.9 0.027 0.35 (0.04 to 0.66)
Pradier et al50 202 (123, 121) Percentage of patients deemed to be adherent
(taking 100% of doses; self-report questionnaire)
Mean=75 Mean=61 0.04 0.34 (0.02 to 0.65)
Put et al35 23 (12, 11) Frequency of non-adherent behaviour over the
last 3 months (self-report questionnaire)
Mean (SD)=6.9
(1.2)
Mean (SD)=8.1
(3.1)
0.50 (−0.30 to 1.30)
Remien et al49 196 (106, 109) Percentage of doses taken during the previous
2 weeks (electronic monitoring)
Mean (SD)=76
(27)
Mean (SD)=60
(34)
0.52 (0.25 to 0.79)
Safren et al44 53 (28, 25) Percentage of prescribed doses taken over the
last 2 weeks (self-report questionnaire)
Mean (SD)=93
(22)
Mean (SD)=94
(10)
−0.06 (−0.59 to 0.47)
Continued
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Table 2 Continued
Extracted data
Study
Sample size
(intervention, control) Adherence definition (assessment measure)
Intervention
group Control group p Value
Effect size
(Hedges’ g)
(95% CI)
Sheeran and
Orbell28
78 (38, 40) Number of once daily doses missed over a
3 week period (self-report questionnaire)
Mean=2.68 Mean=4.85 0.05 0.45 (0.00 to 0.89)
Simoni et al48 114 (57, 57) Percentage of doses taken over the last 7 days
(electronic monitoring)
Mean (SD)=32.3
(42.5)
Mean (SD)
=29.1 (39.7)
0.08 (−0.29 to 0.44)
Smith et al47 17 (8, 9) Percentage of participants taking ≥80% of their
weekly doses (electronic monitoring)
OR=7.8 (2.2 to 28.1) 1.08 (0.41 to 1.74)
Solomon et al43 2087 (1046, 1041) Median % medication possession ratio
(prescription refill data)
Median=49
IQR=7 to 88
Median=41
IQR=2 to 86
0.07 0.08 (−0.01 to 0.17)
Tuldrà et al46 77 (36, 41) Percentage of patients with monthly adherence
≥95% (self-reported number of pills taken)
Mean=94 Mean=69 0.008 0.62 (0.16 to 1.07)
van Es et al32 67 (58, 54) Adherence score on a self-report scale based on
how often medication was taken (never-always)
Mean=7.7 Mean=6.7 0.05 0.48 (0.00 to 0.96)
Wagner et al45 135 (154, 76) Percentage of doses taken during the
intervention period (electronic monitoring)
Mean=83.5 Mean=86.4 0.57 −0.08 (−0.35 to 0.20)
Weber et al33 53 (29, 24) Percentage of patients with monthly adherence
≥95% (electronic monitoring)
Mean=70.8 Mean=50 0.014 0.69 (0.14 to 1.24)
Williams et al31 75 (36, 39) Percentage of doses taken during the
intervention period (pill counts
Mean=58.4 Mean=66 0.162 −0.32 (−0.77 to 0.13)
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form the mainstay of current medication adherence
interventions, and so our research suggests that CBCTs
may be able to elicit adherence beneﬁts beyond the
techniques used in current practice.
The majority of interventions were complex and multi-
faceted, and thus subgroup analysis to explore whether
this is associated with greater effect could not be under-
taken. The subgroup analyses performed revealed that
the effect size was greater when interventions were deliv-
ered in a hospital setting than in a community setting,
but were not inﬂuenced by other variables such as the
type of CBCT, delivery method and personnel or dur-
ation. Further work is necessary to explore the effect of
settings on effect size.
Comparison with other studies
In 2003, Peterson et al53 conducted a meta-analysis of
educational and behavioural interventions to improve
medication adherence in a range of illnesses. The
included studies were all RCTs delivered over similar
time periods to those included in our study. The educa-
tional components and behavioural components such as
changes in dosing schedule and reminders examined by
Peterson et al closely mirror those utilised in the studies
from our meta-analysis which used control groups with
‘active standard care’. Peterson et al reported a correl-
ation coefﬁcient (r) equivalent to a Cohen’s d effect size
of 0.16 (0.08, 0.24). For our study, the effect size for all
studies, when adjusting for publication bias and
reported as Hedges’ g, was 0.20 (0.08, 0.33). This sug-
gests that inclusion of CBCTs strengthens the adherence
improvements gained, if only marginally. Moreover,
Peterson et al report publication bias observed from a
funnel plot of their included studies, but have not made
allowances for this bias via recomputed effect sizes.
Their Cohen’s d value of 0.16 is quite likely exaggerated
by the noted publication bias and thus implies that the
true difference in effect size between the two
meta-analyses may be greater.
An effect size (Hedges’ g) of 0.25 (95% CI 0.07
to 0.42) for studies using MI was calculated, compared
with an effect size of 0.41 (95% CI 0.278 to 0.541) for
non-MI interventions. After adjusting for bias, the esti-
mated Hedges’ g was 0.137 (95% CI −0.067 to 0.341)
Figure 2 Forrest plot for studies included in meta-analysis.
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for studies using MI and 0.356 (95% CI 0.223 to 0.489)
for studies using non-MI interventions. These estimated
effect sizes closely match the effect size calculated
when MI is used as a behavioural intervention in other
healthcare domains14 and thus represent novel
evidence for the wider application of MI techniques
beyond the treatment of substance abuse and gam-
bling. The overlapping CIs of the effect sizes calculated
for MI-based and non-MI based interventions suggest
that MI-based interventions are unlikely to be superior
Figure 3 Funnel plot for studies
included in meta-analysis.
Table 3 Summary of subgroup analyses
Variable Subgroup-A vs subgroup-B
Number of studies (number of
participants) in each subgroup Coefficient (95% CI)
p
Value
Intervention
setting
Hospital vs community 9 (1124) vs 17 (4092) 0.27 (0.01 to 0.54) 0.043
Disease area HIV vs other conditions 14 (1323) vs 12 (3893) 0.05 (−0.23 to 0.33) 0.72
Intervention
components
MI vs no MI component 11 (3538) vs 15 (1678) −0.17 (−0.44 to 0.09) 0.193
Intervention
delivery method
Entirely in person vs other
methods
15 (1663) vs 11 (3553) −0.03 (−0.31 to 0.25) 0.841
Entirely over the telephone vs
other methods
3 (2679) vs 23 (2537) −0.16 (−0.59 to 0.26) 0.442
Both in person and telephone vs
other
7 (775) vs 19 (4441) −0.05 (−0.27 to 0.37) 0.744
Intervention
delivery personnel
Specialist vs Routine HCP 5 (503) vs 12 (1567) −0.01 (−0.46 to 0.26) 0.561
Total intervention
exposure
≤3 h vs >3 h 9 (3061) vs 7 (887) 0.07 (−0.35 to 0.50) 0.728
Control group
type
Explicit active controls vs usual
care (no adherence enhancing
strategies)
13 (3683) vs 13 (1533) 0.09 (−0.18 to 0.37) 0.493
Risk of bias Outcome assessment blinding
vs no outcome assessment
blinding
15 (3555) vs 11 (1661) 0.05 (−0.24 to 0.33) 0.736
Outcome
measures
Objective vs subjective
measured outcomes
14 (3850) vs 12 (1366) −0.16 (−0.44 to 0.11) 0.225
MI, Motivational Interviewing.
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in their efﬁcacy compared with those based on other
CBCTs.
Strengths and weaknesses of our work
This study represents the ﬁrst meta-analysis of MI and
other CBCTs as medication adherence interventions and
has been undertaken with methodological rigour and in
accordance with published guidance.18 A notable
strength of this work is the robust methodological tech-
niques that have been applied to provide an estimate of
effect size which accounts for publication biases, and
thus greater conﬁdence can be placed in the estimate.
The work is also strengthened by restriction to RCTs.
While moderate agreement in abstract screening may
be lower than ideal, this is largely attributable to the
paucity of detail reported in abstracts and complexities
in intervention deﬁnitions, which are known to be prob-
lematic in this domain.11–13 The conservative approach
to abstract screening prevented study exclusion if dis-
agreement was associated with insufﬁcient information
and thus prevented exclusion in error. Heterogeneity
between the included studies was high with an I2
value of 68% (95% CI 52% to 79%) and thus raises
the question as to whether the studies were sufﬁciently
comparable to warrant pooling in a meta-analysis.
While we deﬁned our inclusion criteria to ensure that
studies were as similar as possible (ie, all using a CBCT),
heterogeneity was expected as other factors such as the
populations and disease states studied were more
difﬁcult to control for. Interestingly, the largest study
had a small standardised group difference compared
with most of the other studies which contributed
substantially to the heterogeneity.43 Aside from these
between-study differences, the actual interventions were
variable, as were the deﬁnitions of adherence and assess-
ment tools used.
The differences between subgroups were statistically
non-signiﬁcant in terms of disease area, intervention
components, delivery methods, delivery personnel,
intensity, usual care and risk of bias. However, the statis-
tical power was limited by the small number of studies
included in the subgroup analyses. The analyses may
therefore have failed to detect some important subgroup
differences. Moreover, for variables such as the interven-
tion exposure, meaningful conclusions are difﬁcult to
draw. While the analyses infer that intervention exposure
did not inﬂuence effect size, it is important to remem-
ber that a whole host of variables are at large. It is pos-
sible that briefer interventions used different techniques
or were delivered to different types of recipients com-
pared with longer interventions, and therefore compari-
sons may not be wholly meaningful. Further work may
be necessary to explore whether otherwise identical
interventions (same technique, same population, same
delivery personnel and so forth) differ in effect size
when delivered with different exposure.
Despite these numerous between-study differences, the
core of each intervention was the use of a CBCT to
improve medication adherence, which was comparable
across all studies, and thus we would argue that data
pooling irrespective of heterogeneity was both intuitive
and meaningful.
We have established that receipt of a cognitive-based
behavioural medication adherence intervention is likely
to elicit small improvements in medication adherence,
but the clinical relevance and impact of this improve-
ment remain unknown. Based on the mean adherence
rates in the control groups, mean SDs and the effect size
calculated, it has been possible to estimate the increase
in percentage of doses taken for the intervention groups.
Based on the adjusted Hedges’ g value of 0.205 (0.084 to
0.326), receipt of a CBCT improved adherence (% of
doses taken) by 6.29% (2.58% to 10%). For some medica-
tions, a 6% increase in the percentage of doses taken may
not be of clinical relevance. However, for other medica-
tions such as antiretroviral therapy for HIV, which
requires very high levels of adherence or antiepileptic
therapies with narrow therapeutic windows, a 6%
increase in adherence may have notable clinical rele-
vance. While many included studies provided data on
clinical outcomes, pooling of these data from a diverse
range of studies was not possible.
Implications
Motivational and CBCTs can seemingly be delivered
effectively by routine healthcare professionals, with efﬁ-
cacy applicable to a range of diseases. Efﬁcacy was not
related to intervention exposure. Interestingly, the results
also suggest that these interventions can be delivered via
telephone or face-to-face with comparable efﬁcacy. These
are valuable traits for an adherence intervention which
could be adaptable to a wide range of settings and amen-
able to tailoring to meet individual needs.
The ﬂexibility and adaptability of these techniques
coupled with their frequent simplicity means that practi-
tioners may wish to consider incorporation of these tech-
niques into their consultations when faced with the
need to facilitate medication-related behaviour changes.
RECOMMENDATIONS AND CONCLUSIONS
Further investigation of these techniques as medication
adherence interventions is warranted in order to further
elucidate the characteristics most strongly associated with
efﬁcacy. Studies to determine patient and healthcare
practitioner acceptability of these techniques are also
necessary to establish their role in routine healthcare.
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